Quarterly report pursuant to Section 13 or 15(d)

Composition of Certain Financial Statement Captions

v2.4.0.8
Composition of Certain Financial Statement Captions
6 Months Ended
Jun. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
COMPOSITION OF CERTAIN FINANCIAL STATEMENT CAPTIONS
COMPOSITION OF CERTAIN FINANCIAL STATEMENT CAPTIONS
(In thousands)
June 30,
2013
 
December 31,
2012
Accounts receivable, net:
 
 
 
Accounts receivable
$
23,135

 
$
21,636

Less: allowance for doubtful accounts
(908
)
 
(474
)
 
$
22,227

 
$
21,162

Inventories, net:
 
 
 
Finished products
$
15,169

 
$
17,963

Work in-process
1,253

 
688

Raw materials
4,721

 
4,923

Less: inventory reserve
(1,365
)
 
(1,313
)
 
$
19,778

 
$
22,261

Intangible assets, net:
 
 
 
Technologies
$
52,796

 
$
52,810

Customer relationships
22,839

 
23,088

Product registrations
9,690

 
9,637

Tradenames
3,683

 
3,746

Covenants not to compete
8,660

 
8,662

Other
1,180

 
367

Less:  accumulated amortization
(19,073
)
 
(14,072
)
 
$
79,775

 
$
84,238

Accrued expenses:
 
 
 
Income taxes payable
$
2,421

 
$
1,614

Deferred revenue
3,903

 
1,518

Clinical trials
315

 
50

Professional fees
933

 
675

Employee benefits
3,972

 
3,319

Deferred acquisition payments, net of discount
5,432

 
6,172

Contingent consideration
5,298

 
5,126

Interest payable related to the Notes
2,275

 

Other
6,496

 
6,182

 
$
31,045

 
$
24,656

Other long-term liabilities:
 
 
 
Contingent consideration – Cytochroma
$
49,784

 
$

Contingent consideration – Farmadiet
529

 
532

Contingent consideration – OPKO Diagnostics
12,746

 
11,310

Contingent consideration – FineTech

 
2,578

Contingent consideration – CURNA
549

 
510

Deferred acquisition payments, net of discount
3,983

 
3,931

Mortgages and other debts payable
3,636

 
5,150

Deferred tax liabilities
7,185

 
9,777

Other, including deferred revenue
2,191

 
380

 
$
80,603

 
$
34,168


The change in value of the intangible assets is primarily due to the acquisitions of OPKO Do Brasil Comércio De Produtos Farmacéuticos Ltda ("OPKO Brazil"), previously known as Silcon Comércio, Importacao E Exportacao de Produtos Farmacéuticos e Cosmeticos Ltda, and Cytochroma Inc. (“Cytochroma”), as well as the foreign currency fluctuations between the Chilean and Mexican pesos, the Brazilian Reals, the Euro and the Shekel against the U.S. dollar at June 30, 2013 and December 31, 2012.